Rob Calvert
@RobCalvert18
Followers
1K
Following
3K
Media
425
Statuses
2K
Urologist @nhsUHLG | National Audit @BAUSUrology | Urological Education | Interested in technology in general | Father of 4 | views my own
Liverpool
Joined September 2020
So is looks like @SpaceX are actually going to go full in on hyperscaling space based data centres 👀 Many technical challenges to overcome
Here's why I think SpaceX is going public soon. https://t.co/KEZIjhEsTH
0
0
0
Please get your submissions in for the BAUS Recurrent UTI National Audit
⚠️Submission deadline for BAUS-related snapshot audits - BOOMERANG - extended until 27 Dec inclusively. 👀Investigation & Referral of Women with recurrent urinary Tract Infection using recent guidance Relevant info sent to all Clinical Audit Leads. 📲Scan the QR code for more
0
0
4
"We should reimagine the firm for the 21st century," argues this Opinion article. "That means team based hospital medicine with clear medical leadership and continuity" https://t.co/dvji40v2N7
bmj.com
When I graduated in 1995, hospital medicine in the UK was organised around a “firm”—a team of consultants, registrars, senior house officers, and house officers who knew their patients, and each...
0
8
10
🚨New podcast series alert 🚨 Prostate Perspectives - a 3-part podcast series bringing key insights to your headphones. Explore the latest thinking on prostate cancer screening, diagnosis and management. 🎙️🎧Listen now: https://t.co/braFeXSGXo
#ProstateCancer #Podcasts
0
2
6
11
94
282
📢 Abstract submissions for #BAUS26 are OPEN! Got groundbreaking research or a bold new idea in urology? We want to see it. 🕚Deadline: 11:00am | 15 Jan 2026 Submit now & help shape the future ➡️ https://t.co/dEk5IAxtaI
#Urology #Innovation #BAUS26
0
9
11
Adjuvant Pembrolizumab effect on overall survival particularly marked at 5 years (HR 0.36) in patients where oligometastatic renal cell carcinoma has been resected and there is no evidence of disease post-op.
#SUO25 5y follow-up from KEYNOTE-564 🧪 Adjuvant pembrolizumab in high-risk ccRCC after nephrectomy 👥 n=994 | FU: 69.5 mo 🔹 5y DFS: 60.9% vs 52.2% (HR 0.71) 🔹 5y OS: 87.7% vs 82.3% (HR 0.66) 🔹 M1 NED: HR 0.36 ✅ No new TRAEs in >3y ✅ 1st adjuvant Rx in RCC with OS benefit
0
0
2
To celebrate five years of #AlphaFold, we’re making The Thinking Game available on YouTube. 🧬 Get a candid look at the triumphs, the challenges and the pivotal moments that led to a breakthrough on a 50-year-old grand challenge in biology. Stream for free on @YouTube →
119
646
4K
Great collaboration this week as BAUS joined BAUN, @BJUIjournal and @TUF_tweets for a joint strategy session on stronger partnerships and future opportunities in urology. A huge thank you to BJUI for hosting! 👏 #Urology #Collaboration #BAUS
0
4
23
8/ If a QALY is priced generously for roads and rail, but at a bargain-basement level for the NHS, we’re not simply “following the evidence” – we’re making political choices about how much health we are willing to buy, and for whom.
0
0
0
7/ So yes, raising the NICE threshold is welcome and long overdue. But if we really believed our own Green Book valuation of health (~£70k/QALY), we might take a very different view on interventions like targeted prostate cancer screening.
1
0
0
6/ If you build a model on a very low threshold, national screening programmes – even those targeted at high-risk men – are much more likely to be labelled “not cost-effective”, regardless of the lives saved or years of good-quality life gained.
1
0
0
5/ One example: prostate cancer screening. The recent SCHARR modelling for the UK National Screening Committee evaluated screening at a decision threshold of just £20k per QALY – the very bottom of the old NICE range. https://t.co/Gsluje18bA
1
0
0
4/ So the government effectively runs with two prices for the same unit of health: ~£25k–£35k inside the NHS, ~£70k when justifying non-NHS spending. That gap isn’t technical; it’s a choice, and it has consequences. https://t.co/svhp3Zxww3
abpi.org.uk
In this piece, Victoria Jordan, ABPI's Director, Value and Access Policy, explains why the government must increase NICE’s baseline threshold to ensure that NHS patients benefit from timely access to...
1
0
0
3/ Meanwhile, HM Treasury’s Green Book tells other departments to value a QALY at around £70,000 when doing options appraisal – for transport safety, air quality, prevention policies and more. https://t.co/kgR4gZU7VC
gov.uk
1
0
0
2/ For 26 years the threshold was frozen at £20k–£30k while prices rose. If it had simply tracked CPI since 1999, today’s range would be roughly £44k–£66k per QALY. So even this “rise” still leaves us well below an inflation-uprated level.
1
0
0
🧵 1/ NICE has quietly confirmed a long-overdue change: its cost-effectiveness threshold for new drugs will rise from £20k–£30k to £25k–£35k per QALY – the first increase since 1999. @NICEComms @BAUSurology
https://t.co/etWunel3rN
nice.org.uk
Changes to NICE’s cost-effectiveness thresholds confirmed
3
0
0
📣 We are recruiting faculty for this year’s BSoT Urology ST3 Interview Course 📆 16-17th Feb 2026 ✍️ If interested in helping out, please fill in the short form below. Your support would be hugely appreciated! https://t.co/8cScDpULRt
docs.google.com
Event Date and Timing: BAUS Section of Trainees (BSOT) course: 16th and 17th of February 2026 AM session 0900 - 1230; PM session 1300 - 1630 Certificates will be provided for faculties contribution...
1
5
9
Prostate cancer high risk groups and approximate relative risk
0
0
11